Study of CS-3150 in Patients With Essential Hypertension

Clinical Trial Description

Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg compared to Eplerenone in patients with essential hypertension.

Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg compared to 2.5 mg. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03708601` - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting	`NCT05503953` - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS	Phase 3
Recruiting	`NCT05526703` - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy	Phase 3
Completed	`NCT06395194` - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension	Phase 3
Not yet recruiting	`NCT06418074` - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity	N/A
Completed	`NCT02944734` - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension	Phase 2
Withdrawn	`NCT02096939` - Microvascular Function in Primary Aldosteronism	N/A
Recruiting	`NCT01956786` - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine	Phase 2/Phase 3
Completed	`NCT02553512` - Helius in Hypertension-I: The UK Hypertension Registry	N/A
Completed	`NCT01198249` - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension	Phase 1
Completed	`NCT01001572` - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension	Phase 3
Recruiting	`NCT00380289` - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension	N/A
Completed	`NCT00139698` - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension	Phase 3
Completed	`NCT00288184` - Uric Acid in Essential Hypertension in Children	Phase 2
Completed	`NCT01289886` - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects	Phase 1
Not yet recruiting	`NCT06041529` - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension	Phase 4
Completed	`NCT04470830` - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed	`NCT00758524` - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension	Phase 2
Recruiting	`NCT05109013` - Juvenile Essential Arterial Hypertension and Vascular Function
Completed	`NCT00741585` - Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment	Phase 4

NCT number	NCT02890173
Study type	Interventional
Source	Daiichi Sankyo, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	September 2016
Completion date	July 11, 2017

Study of CS-3150 in Patients With Essential Hypertension — ESAX-HTN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms